A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.

@article{Hong2011AP1,
  title={A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.},
  author={David S. Hong and Razelle Kurzrock and Yun Myung Oh and Jennifer J. Wheler and Aung S. Naing and Les Brail and Sophie Callies and Valerie A M Andre and Sunil K Kadam and Aejaz Nasir and Timothy R. Holzer and Funda Meric-Bernstam and Mayer Fishman and George Rajan Simon},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 20},
  pages={6582-91}
}
PURPOSE The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors. This phase I study sought an appropriate LY2275796 dose in patients with advanced tumors. EXPERIMENTAL DESIGN A 3-day loading dose, then weekly maintenance doses, were given to 1 to 3 patient cohorts, beginning with 100 mg and escalating. Plasma samples were collected to determine LY2275796 concentrations and… CONTINUE READING